References
[1] Tasian SK, Hunger SP. Genomic characterization of paediatric
acute lymphoblastic leukaemia: an opportunity for precision medicine
therapeutics. Br J Haematol. 2017;176:867-82.
[2] Tang J, Yu J, Cai J, Zhang L, Hu S, Gao J, et al. Prognostic
factors for CNS control in children with acute lymphoblastic leukemia
treated without cranial irradiation. Blood. 2021;138:331-43.
[3] Xue Yujuan, Lu Aidong, Wu Jun, Zuo Yingxi, Jia Yueping, Zhang
Leping. Molecular response and prognosis of pediatric patients with
Ph-positive acute lymphoblastic leukemia treated by tyrosine kinase
inhibitors with chemotherapy. Chin J Appl Clin Pediatr. 2020;35:201-5.
[4] Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of
Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia
Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical
Trial. JAMA Oncol. 2020;6:358-66.
[5] WANG Liang, XU Jing, CHEN Fa-dong. A case of reversible
pulmonary arterial hypertension caused bydasatinib and analysis of
clinical features. Fudan University Journal of Medical Sciences.
2022;49:469-74.
[6] Haematology Group of Pediatrics Branch of Chinese Medical
Association,Editorial Board of the Chinese Journal of Pediatrics.
Recommendations for the treatment of acute lymphoblastic leukemia in
children (fourth revision). Chinese Journal of Pediatrics.
2014;52:641-4.
[7] Kato M, Manabe A. Treatment and biology of pediatric acute
lymphoblastic leukemia. Pediatr Int. 2018;60:4-12.
[8] Ibrahim U, Saqib A, Dhar V, Odaimi M. Dasatinib-induced
pulmonary arterial hypertension - A rare late complication. J Oncol
Pharm Pract. 2019;25:727-30.
[9] Jose A, Rafei H, Ahari J. Combination targeted pulmonary
hypertension therapy in the resolution of Dasatinib-associated pulmonary
arterial hypertension. Pulm Circ. 2017;7:4 803-7.
[10] Walid R. Reversible severe pulmonary hypertension secondary to
dasatinib in a patient with chronic myeloid leukemia. Leukemia research.
2009;33:861-4.
[11] Mattei D,Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A.
Reversible dasatinib-induced pulmonary arterial hypertension and right
ventricle failure in a previously allografted CML patient. Bone Marrow
Transplant. 2009;43:967-8.
[12] Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S,
Bokemeyer C, Brümmendorf TH, Klose H. Multi tyrosine kinase inhibitor
dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
BMC Pulm Med. 2011;11:30.
[13] Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary
arterial hypertension likely related to long-term, low-dose dasatinib
treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4-6.
[14] Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E,
Rosenkranz S. Fully reversible pulmonary arterial hypertension
associated with dasatinib treatment for chronic myeloid leukaemia. Eur
Respir J. 2011;38: 218-20.
[15] Sano M, Saotome M, Urushida T, Katoh H, Satoh H, Ohnishi K, et
al. Pulmonary arterial hypertension caused by treatment with dasatinib
for chronic myeloid leukemia -critical alert. Intern Med.
2012;51:2337-40.
[16] Groeneveldt JA, Gans SJ, Bogaard HJ, Vonk-Noordegraaf A.
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5
inhibition. Eur Respir J. 2013;42:869-70.
[17] Liu Bingcheng W Y, Mi Yingchang, Wang Jianxiang. Reversible
pulmonary arterial hypertension related to dasatinib in the treatment
for chronic myelogenous leukemia: a case report and literature review.
Chin J Hematol. 2014;35:581-6.
[18] Liu Bingcheng, Wang Ying, Mi Yingchang, Wang Jianxiang.
Reversible dasatinib-related pulmonary arterial hypertension diagnosed
by noninvasive echocardiography. Kaohsiung J Med Sci. 2015;31:165-6.
[19] Buchelli Ramirez HL, Álvarez Álvarez CM, Rodríguez Reguero JJ,
García Clemente MM, Casan Clarà P. Reversible pre-capillary pulmonary
hypertension due to dasatinib. Respir Care. 2014;59:e77-80.
[20] Hong JH, Lee SE, Choi SY, Kim SH, Jang EJ, Bang JH,et al.
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for
Chronic Myeloid Leukemia. Cancer Res Treat. 2015;47:937-42.
[21] Jin Jin, Xu Xiaomao, Wang Chen. Repeated partially reversible
pulmonary arterial hypertension related to dasatinib: a case report and
literature review. Chin J Tuberc Respir Dis. 2016;39:83-7.
[22] Seegobin K, Babbar A, Ferreira J, Lyons B, Cury J, Seeram V. A
case of worsening pulmonary arterial hypertension and pleural effusions
by bosutinib after prior treatment with dasatinib. Pulm Circ. 2017;7:
808-12.
[23] Skride A, Sablinskis M, Sablinskis K, Lesina K, Lejnieks A,
Lejniece S. Pulmonary arterial hypertension in a patient treated with
dasatinib: a case report. J Med Case Rep. 2017;11:362.
[24] Nishimori M, Honjo T, Kaihotsu K, Sone N, Yoshikawa S, Imanishi
J, et al. Dasatinib-Induced Pulmonary Arterial Hypertension Treated with
Upfront Combination Therapy. Case Rep Cardiol. 2018;2018:3895197.
[25] Zhao Yangyang, Qike Cao, Yunshan Yan, Xiaojing, Fu Yuan, Chen
Yang, et al. A case of pulmonary hypertension due to dasatinib confirmed
by right heart catheterization and review of the literature. Journal of
Lanzhou University(Medical Sciences). 2018;44:31-6.
[26] Toya T, Nagatomo Y, Kagami K, Adachi T. Dasatinib-induced
pulmonary arterial hypertension complicated with scleroderma: a case
report. Eur Heart J Case Rep. 2019;3: ytz025.
[27] Orlikow E, Weatherald J, Hirani N. Dasatinib-Induced Pulmonary
Arterial Hypertension. Can J Cardiol. 2019;35:1604 e1- e3.
[28] Duvvuri PD, Liu J, Bhardwaj C. A 59-Year-Old Woman With
Shortness of Breath and Chest Pain. Chest. 2020;158:e65-e9.
[29] Zeng Qixian, Luo Qin, Zhao Zhihui, Zhao Qing, Liu Zhihong,
Xiong Changming. Dasatinib induces pulmonary arterial hypertension: A
case report. China Clinical Case Results Database, 2022;4:e642.
[30] Kim JC, Shin SH, Yi HG, Kim SH, Woo SI, Kim DH, et al.
Rapid-onset pulmonary arterial hypertension in a patient with acute
lymphoblastic leukemia treated with dasatinib. Herz. 2013;38:931-3.
[31] Taçoy G, Çengel A, Özkurt ZN, Türkoğlu S. Dasatinib-induced
pulmonary hypertension in acute lymphoblastic leukemia: case report.
Turk Kardiyol Dern Ars. 2015;43:78-81.
[32] Li Ji, Zhao Huihui, Li Yanru, Zhu Yu, Lu Ruinan, Zhang Xiaoyan,
et al. Dasatinib cuses reversible pulmonary hypertension, pleural
effusion, pericardial effusion and literature review in a case of
Ph-positive acute lymphoblastic leukemia. Journal of Nanjing Medical
University (Natural Science Edition). 2016;3:764-8.